Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies
Background: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. Methods: We describe 2 phase I studies: KP1461-101 (double-blind, placebo-controlled, single, escalating doses, 100 to 1600 mg study in 42 non-HIV-infected participants) and KP-1461-102 (do...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publishing
2011-08-01
|
| סדרה: | Journal of the International Association of Providers of AIDS Care |
| גישה מקוונת: | https://doi.org/10.1177/1545109711406442 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|